[go: up one dir, main page]

WO2001000824A3 - HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS - Google Patents

HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS Download PDF

Info

Publication number
WO2001000824A3
WO2001000824A3 PCT/JP2000/003944 JP0003944W WO0100824A3 WO 2001000824 A3 WO2001000824 A3 WO 2001000824A3 JP 0003944 W JP0003944 W JP 0003944W WO 0100824 A3 WO0100824 A3 WO 0100824A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
hydrophobic domains
dnas encoding
dnas
human
Prior art date
Application number
PCT/JP2000/003944
Other languages
French (fr)
Other versions
WO2001000824A2 (en
Inventor
Seishi Kato
Tomoko Kimura
Original Assignee
Sagami Chem Res
Protegene Inc
Seishi Kato
Tomoko Kimura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagami Chem Res, Protegene Inc, Seishi Kato, Tomoko Kimura filed Critical Sagami Chem Res
Priority to EP00937279A priority Critical patent/EP1194543A2/en
Priority to JP2001506817A priority patent/JP2003503054A/en
Priority to AU52499/00A priority patent/AU5249900A/en
Publication of WO2001000824A2 publication Critical patent/WO2001000824A2/en
Publication of WO2001000824A3 publication Critical patent/WO2001000824A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)

Abstract

The present invention provides human proteins having hydrophobic domains, DNAs encoding these proteins, expression vectors for these DNAs, transformed eukaryotic cells expressing these DNAs and antibodies directed to these proteins.
PCT/JP2000/003944 1999-06-24 2000-06-16 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS WO2001000824A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00937279A EP1194543A2 (en) 1999-06-24 2000-06-16 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
JP2001506817A JP2003503054A (en) 1999-06-24 2000-06-16 Human protein having hydrophobic domain and DNA encoding the same
AU52499/00A AU5249900A (en) 1999-06-24 2000-06-16 Human proteins having hydrophobic domains and dnas encoding these proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17806599 1999-06-24
JP11/178065 1999-06-24

Publications (2)

Publication Number Publication Date
WO2001000824A2 WO2001000824A2 (en) 2001-01-04
WO2001000824A3 true WO2001000824A3 (en) 2001-07-05

Family

ID=16042010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/003944 WO2001000824A2 (en) 1999-06-24 2000-06-16 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS

Country Status (4)

Country Link
EP (1) EP1194543A2 (en)
JP (1) JP2003503054A (en)
AU (1) AU5249900A (en)
WO (1) WO2001000824A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053737A1 (en) * 2000-12-28 2002-07-11 Asahi Kasei Kabushiki Kaisha Nf-kb activating gene

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021328A2 (en) * 1996-11-13 1998-05-22 Sagami Chemical Research Center Human proteins having transmembrane domains and dnas encoding these proteins
WO1999018126A1 (en) * 1997-10-07 1999-04-15 Ono Pharmaceutical Co., Ltd. POLYPEPTIDE, cDNA ENCODING THE POLYPEPTIDE, AND USE OF THE BOTH
WO1999031236A2 (en) * 1997-12-17 1999-06-24 Genset EXTENDED cDNAs FOR SECRETED PROTEINS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021328A2 (en) * 1996-11-13 1998-05-22 Sagami Chemical Research Center Human proteins having transmembrane domains and dnas encoding these proteins
WO1999018126A1 (en) * 1997-10-07 1999-04-15 Ono Pharmaceutical Co., Ltd. POLYPEPTIDE, cDNA ENCODING THE POLYPEPTIDE, AND USE OF THE BOTH
WO1999031236A2 (en) * 1997-12-17 1999-06-24 Genset EXTENDED cDNAs FOR SECRETED PROTEINS

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
D'ANDREA ET AL: "Molecular Cloning of NKB1. A Natural Killer Cell Receptor for HLA-B Allotypes", JOURNAL OF IMMUNOLOGY,US,THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 155, no. 5, 1 September 1995 (1995-09-01), pages 2306 - 2310, XP002111500, ISSN: 0022-1767 *
DATABASE EMBL EBI; 16 April 1998 (1998-04-16), STRAUSBERG: "National cancer institute, Cancer genome anatomy project", XP002151124 *
DATABASE EMBL EBI; 25 September 1996 (1996-09-25), HILLIER ET AL.: "Generation and analysis of 280,000 human expressed sequence tags", XP002151123 *
DATABASE EMBL EBI; 9 April 1999 (1999-04-09), NAGASE ET AL.: "Homo sapiens mRNA for KIAA1007, partial cds.", XP002151125 *
DATABASE WPI Section Ch Week 199923, Derwent World Patents Index; Class B04, AN 1999-277254, XP002151126 *
GILLEN C M ET AL: "Molecular cloning and functional expression of the K-Cl cotransporter from rabbit, rat, and human", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 271, no. 27, 5 July 1996 (1996-07-05), pages 16237 - 16244, XP002119528, ISSN: 0021-9258 *
KYTE J ET AL: "A SIMPLE METHOD FOR DISPLAYING THE HYDROPATHIC CHARACTER OF A PROTEIN", JOURNAL OF MOLECULAR BIOLOGY,GB,LONDON, vol. 157, no. 1, 5 May 1982 (1982-05-05), pages 105 - 132, XP000609503, ISSN: 0022-2836 *
NAGASE ET AL.: "Prediction of the coding sequences of unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro", DNA RESEARCH, vol. 6, 26 February 1999 (1999-02-26), pages 63 - 70, XP000952912 *

Also Published As

Publication number Publication date
WO2001000824A2 (en) 2001-01-04
JP2003503054A (en) 2003-01-28
EP1194543A2 (en) 2002-04-10
AU5249900A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
WO2001049728A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO2000005367A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
WO2001012660A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO2000029448A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
AU4189799A (en) Prostate growth-associated membrane proteins
NO20016243D0 (en) Anti-alpha-beta3 recombinant human antibodies, nucleic acids encoding the same, and methods of recycling
WO2001002563A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
AU2002228972A1 (en) Polynucleotide encoding chimeric protein and related vectors, cells, and methods of expression thereof
EP1571216A3 (en) Phosphodiesterase 8A
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
WO2000069884A3 (en) Compositions isolated from skin cells and methods for their use
WO2002036627A3 (en) Interferons, uses and compositions related thereto
MXPA01003868A (en) Apomixis conferred by expression of serk interacting proteins.
HUP0103152A3 (en) Monoclonal antibodies directed against the g3bp protein, and uses
WO1999049038A3 (en) Human calcium-binding proteins
WO2001004297A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
WO1999009182A3 (en) Rab proteins
WO2001000824A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
AU2452301A (en) Protein methylarginine-specific antibodies
ZA99677B (en) Placental protein 13.
WO2000000506A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
WO2000019210A3 (en) Determining the mechanism of beta-amyloid peptide generation
WO2001000662A3 (en) The use of human fgh-8 polypeptides as neurotrophic agents
WO2000052161A3 (en) Leukocyte- and blood-associated proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 506817

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000937279

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000937279

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 200208527

Country of ref document: ZA

WWW Wipo information: withdrawn in national office

Ref document number: 2000937279

Country of ref document: EP